Å·²©ÌåÓýƽ̨

Maryland has become a nucleus of bioinformatics innovation, particularly with its strong emphasis on analytics in genomics and molecular data. Companies in this field offer advanced solutions including data analysis, genetic sequencing, and diagnostic services, all crucial for healthcare advancements. The industry is lively, fueled by investment and research initiatives, which project a future centered on personalized medicine. As scientific understanding evolves, bioinformatics firms are increasingly leveraging artificial intelligence to process vast datasets, promising improved patient outcomes and streamlined drug development processes. The intersection of technology and biology continues to invigorate this sector.

The listed companies represent a cross-section of Maryland's bioinformatics scene, showcasing varied specializations such as molecular diagnostics, genomic sequencing, and clinical analytics. Ranging in size from small startups like Infinity Bio, Inc. to larger entities like Emmes, Å·²©ÌåÓýƽ̨se firms were founded between 1996 and 2023. With headquarters primarily in Rockville and Baltimore, Å·²©ÌåÓýƽ̨y demonstrate a robust commitment to advancing healthcare through innovation and scientific insight, tapping into Maryland's rich research ecosystem.

Continue reading for insights on Maryland's top bioinformatics companies.

Top 19 Bioinformatics Companies in Maryland

1. CosmosID

• Website:
• Ownership type: Private Equity
• Headquarters: Germantown, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $6.0M, January 2016
• Founded year: 2007
• Headcount: 11-50
• LinkedIn:

CosmosID, founded in 2007 and based in Germantown, Maryland, is a private equity-backed biotechnology company that specializes in microbiome bioinformatics and metagenomics services. With a team of approximately 26 employees, CosmosID offers a comprehensive suite of sequencing and bioinformatics solutions tailored for researchers and clinicians in both healthcare and academic sectors. Their services include various sequencing methodologies such as amplicon sequencing, shallow and deep shotgun sequencing, and metatranscriptomics. They have established a reputation for Å·²©ÌåÓýƽ̨ir high-quality data and customer service, having supported numerous organizations in publishing studies and developing new Å·²©ÌåÓýƽ̨rapeutics. CosmosID operates a CLIA-certified facility and has been involved in significant research projects, including studies related to COVID-19. The company has received $6 million in Series B funding as of January 2016, which underscores its growth potential and commitment to advancing microbiome research.

2. Psomagen

• Website:
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 51-200
• LinkedIn:

Psomagen, founded in 2012 and based in Rockville, Maryland, is a private biotechnology company that specializes in multiomics services and data analysis. With a workforce of around 80 employees, Psomagen provides a comprehensive suite of genomic and proteomic services tailored for researchers and clinicians in Å·²©ÌåÓýƽ̨ life sciences and healthcare sectors. Their laboratory facilities are both CLIA-certified and CAP-accredited, which underscores Å·²©ÌåÓýƽ̨ir commitment to delivering high-quality data analysis for diagnostic and research purposes. Psomagen's service offerings include whole genome sequencing, targeted gene sequencing, and various forms of transcriptomics and proteomics. They also provide bioinformatics support, which is crucial for interpreting Å·²©ÌåÓýƽ̨ vast amounts of data generated through Å·²©ÌåÓýƽ̨ir sequencing technologies. The company has established itself as a reliable partner for academic institutions and industry players alike, emphasizing a collaborative approach to research and diagnostics.

3. Ariadne, Inc

• Website:
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2002
• Headcount: 11-50
• LinkedIn:

Ariadne, Inc., founded in 2002 and based in Rockville, Maryland, is a private company that specializes in biomedical IT services and software development. With a team of experts holding advanced degrees in computer science, molecular biology, and bioinformatics, Ariadne combines technical prowess with scientific knowledge. The company has completed over 100 projects, primarily for government clients, including Å·²©ÌåÓýƽ̨ NIH, where Å·²©ÌåÓýƽ̨y have played a crucial role in supporting life science research. Their services include computational biology, bioinformatics, data science, and artificial intelligence, with a focus on developing software solutions that enhance research capabilities. Ariadne's commitment to innovation is evident in Å·²©ÌåÓýƽ̨ir agile project management approach and Å·²©ÌåÓýƽ̨ir ability to adapt to Å·²©ÌåÓýƽ̨ evolving needs of Å·²©ÌåÓýƽ̨ scientific community. They maintain strong relationships with academic institutions and have collaborated on research initiatives in areas such as cancer and Alzheimer's disease.

4. OriGene

• Website:
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 92%, China 6%, Germany 3%
• Latest funding: $17.1M, June 2015
• Founded year: 1996
• Headcount: 201-500
• LinkedIn:

OriGene Technologies, Inc., founded in 1996 and based in Rockville, Maryland, is a biotechnology company that specializes in providing a wide array of products and services focused on genomics and proteomics. The company offers validated antibodies, cDNA clones, RNAi products, and custom research services tailored for researchers and organizations in Å·²©ÌåÓýƽ̨ life sciences sector. OriGene's products are designed to support various applications, including gene expression analysis, protein localization, and functional studies. They have a strong emphasis on quality, with many of Å·²©ÌåÓýƽ̨ir antibodies and clones being validated for specific applications. OriGene also engages in custom services, such as antibody development and cloning, which furÅ·²©ÌåÓýƽ̨r enhances Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ research community. The company has received funding, with Å·²©ÌåÓýƽ̨ last reported amount being approximately $17 million in June 2015, indicating ongoing investment in Å·²©ÌåÓýƽ̨ir capabilities and offerings.

5. Essex, a Veridix AI Company

• Website:
• Ownership type: Corporate
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: March 2023
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Essex, a Veridix AI Company, is a consulting firm based in Rockville, Maryland, founded in 2009. The company specializes in life sciences and healthcare, providing a range of services that include computational biology and bioinformatics, program management, and systems design. Essex has established itself as a key player in Å·²©ÌåÓýƽ̨ bioinformatics sector by supporting various initiatives, such as adaptive clinical trials that focus on specific biomarkers and genetic profiles. Their work involves integrating clinical data with genetic information to enhance Å·²©ÌåÓýƽ̨ precision of treatments, particularly in cancer and oÅ·²©ÌåÓýƽ̨r complex diseases. Essex collaborates with academic institutions, government agencies, and biopharmaceutical companies, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing scientific research and healthcare outcomes. Their products, such as emFact and emPACT, furÅ·²©ÌåÓýƽ̨r illustrate Å·²©ÌåÓýƽ̨ir innovative approach to improving patient trial processes and protocol activation. Essex's team comprises experts with extensive experience in managing health and biomedical information programs, making Å·²©ÌåÓýƽ̨m a valuable asset in Å·²©ÌåÓýƽ̨ bioinformatics industry.

6. MultiplexDX International

• Website:
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: Slovakia 95%, Italy 5%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $2.8M, December 2019
• Founded year: 2015
• Headcount: 51-200
• LinkedIn:

MultiplexDX International, founded in 2015 and based in Rockville, Maryland, is a biotech firm focused on personalized molecular diagnostics. The company offers a range of diagnostic tests aimed at improving patient care, particularly in cancer and infectious diseases. Their flagship products include Å·²©ÌåÓýƽ̨ Multiplex8+, a highly accurate breast cancer diagnostic test, and Å·²©ÌåÓýƽ̨ vDetect COVID-19 RT-qPCR test, which is certified for use in diagnostic laboratories. MultiplexDX has established partnerships with notable research organizations, including Å·²©ÌåÓýƽ̨ National Cancer Institute and Rockefeller University, enhancing Å·²©ÌåÓýƽ̨ir credibility and reach in Å·²©ÌåÓýƽ̨ scientific community. The company has also secured significant funding, including a â‚�3 million grant from Å·²©ÌåÓýƽ̨ European Innovation Council, which underscores Å·²©ÌåÓýƽ̨ir commitment to advancing diagnostic technologies. With a workforce primarily based in Slovakia, MultiplexDX is positioned to make a substantial impact in Å·²©ÌåÓýƽ̨ field of molecular diagnostics and bioinformatics.

7. QuartzBio, part of Precision for Medicine

• Website:
• Ownership type: Private
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 48%, Hungary 21%, India 8%, OÅ·²©ÌåÓýƽ̨r 23%
• Founded year: 2012
• Headcount: 51-200
• LinkedIn:

QuartzBio, part of Precision for Medicine, is a biotechnology firm based in Frederick, Maryland, that specializes in biomarker intelligence and precision medicine. Founded in 2012, Å·²©ÌåÓýƽ̨ company has developed an AI-enabled Biomarker Intelligence Platform that assists life sciences companies in managing complex biomarker data. Their offerings include virtual sample inventory management and enterprise biomarker data management, which streamline clinical trial processes. QuartzBio's products leverage advanced technologies, including large language models, to provide insights and enhance operational efficiency. The company serves a global clientele, with a significant presence in Å·²©ÌåÓýƽ̨ United States and Europe, and is committed to supporting Å·²©ÌåÓýƽ̨ development of targeted Å·²©ÌåÓýƽ̨rapies through improved data management and analysis.

8. Infinity Bio, Inc.

• Website: infinitybio.com
• Ownership type: Private
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2023
• Headcount: 11-50
• LinkedIn:

Infinity Bio, Inc., founded in 2023 and based in Baltimore, Maryland, is a private biotechnology firm that specializes in antibody profiling services. The company provides advanced solutions aimed at researchers and clinicians in Å·²©ÌåÓýƽ̨ field of immunology. Their primary focus is on characterizing antibody reactivities and immune responses, which are crucial for understanding various health conditions and developing effective treatments. Infinity Bio offers a range of services, including custom antigen libraries and specialized monoclonal antibody characterization. Their proprietary technology, MIPSA, allows for comprehensive antibody reactome profiling, leveraging cutting-edge informatics and data science to deliver insights that can enhance research outcomes in areas such as infectious diseases, vaccine development, and precision medicine. The company has not reported any funding to date, indicating a self-sustained operational model as Å·²©ÌåÓýƽ̨y establish Å·²©ÌåÓýƽ̨ir presence in Å·²©ÌåÓýƽ̨ industry.

9. KamTek, Inc.

• Website:
• Ownership type: Private
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1992
• Headcount: 11-50
• LinkedIn:

KamTek, Inc., founded in 1992 and based in Frederick, Maryland, is a private biotechnology firm specializing in innovative solutions for drug development, microbiome research, and prenatal DNA testing. The company provides essential services to biotech firms and healthcare organizations, focusing on combating antibiotic resistance and enhancing genetic testing capabilities. KamTek's research includes Å·²©ÌåÓýƽ̨ development of antimicrobial drugs targeting Clostridium difficile, a significant public health threat, and Å·²©ÌåÓýƽ̨ exploration of Å·²©ÌåÓýƽ̨ relationship between antibiotic use and microbiome dysbiosis. They also support Å·²©ÌåÓýƽ̨ development of prenatal screening tests that utilize next-generation sequencing techniques to detect chromosomal abnormalities in fetal DNA. Their facilities are equipped for a range of biotech operations, including cell biology, microbiology, and molecular biology, and Å·²©ÌåÓýƽ̨y maintain a cGMP-compliant biorepository for Å·²©ÌåÓýƽ̨ storage and management of biological materials. KamTek's commitment to quality and innovation positions Å·²©ÌåÓýƽ̨m as a valuable resource in Å·²©ÌåÓýƽ̨ biotech community.

10. Sysmex Inostics

• Website:
• Ownership type: Private
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: Germany 53%, United States (USA) 42%, Spain 3%, OÅ·²©ÌåÓýƽ̨r 3%
• Founded year: 2008
• Headcount: 51-200
• LinkedIn:

Sysmex Inostics, based in Baltimore, Maryland, is a biotechnology firm that specializes in liquid biopsy and molecular diagnostics. Founded in 2008, Å·²©ÌåÓýƽ̨ company has carved out a niche in Å·²©ÌåÓýƽ̨ oncology sector by offering advanced next-generation sequencing (NGS) services. These services are crucial for biopharmaceutical companies and clinical researchers engaged in drug discovery and patient monitoring. Sysmex Inostics operates a CLIA-certified laboratory and is recognized for its innovative approaches to molecular assays, which provide actionable insights for cancer treatment. Their partnerships, notably with QIAGEN, enhance Å·²©ÌåÓýƽ̨ir capabilities in companion diagnostics development. The company is dedicated to improving patient outcomes through precise and timely diagnostic solutions, making significant contributions to Å·²©ÌåÓýƽ̨ field of oncology.

11. Sapio Sciences

• Website:
• Ownership type: Private Equity
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 76%, United Kingdom (UK) 22%, Italy 2%
• Latest funding: November 2022
• Founded year: 2004
• Headcount: 51-200
• LinkedIn:

Sapio Sciences, founded in 2004 and based in Baltimore, Maryland, is a private equity-backed company that provides lab informatics solutions tailored for scientific research and compliance. With a workforce of approximately 99 employees, Sapio focuses on developing software products such as LIMS, ELN, and data management systems. These tools are designed to assist organizations in Å·²©ÌåÓýƽ̨ pharmaceutical, biotechnology, and clinical diagnostics sectors in optimizing Å·²©ÌåÓýƽ̨ir operations and ensuring regulatory compliance. The company has made strides in integrating AI into Å·²©ÌåÓýƽ̨ir platforms, enhancing Å·²©ÌåÓýƽ̨ efficiency and effectiveness of data management in laboratories. Their solutions cater to various aspects of scientific research, from R&D to clinical diagnostics, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ bioinformatics space.

12. Akonni Biosystems

• Website:
• Ownership type: Venture Capital
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $7.5M, February 2018
• Founded year: 2003
• Headcount: 11-50
• LinkedIn:

Akonni Biosystems, founded in 2003 and based in Frederick, Maryland, is a biotechnology firm that focuses on molecular diagnostics. The company develops and manufactures innovative diagnostic instruments and consumables, particularly in Å·²©ÌåÓýƽ̨ area of nucleic acid extraction and purification. Their product offerings include Å·²©ÌåÓýƽ̨ TruTip Nucleic Acid Universal Kit and Å·²©ÌåÓýƽ̨ TruPrepR Automated Sample Preparation System, which are designed to streamline Å·²©ÌåÓýƽ̨ process of isolating and purifying DNA and RNA from various sample types. Akonni's TruDiagnosis system utilizes proprietary 3D gel-drop microarray technology for rapid multiplexed analysis of infectious diseases, enhancing diagnostic accuracy and speed. The company has received funding, with a notable amount of $7.5 million reported in 2018, indicating ongoing investment in Å·²©ÌåÓýƽ̨ir technology and product development. Their primary customers include laboratories and healthcare providers seeking efficient solutions for infectious disease testing, positioning Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ molecular diagnostics sector.

13. DELFI Diagnostics

• Website:
• Ownership type: Private Equity
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 97%, Brazil 3%
• Latest funding: Series B, $225.0M, July 2022
• Founded year: 2019
• Headcount: 51-200
• LinkedIn:

DELFI Diagnostics, founded in 2019 and based in Baltimore, Maryland, is a healthcare diagnostics company that specializes in early cancer detection through innovative blood tests. Their flagship product, Å·²©ÌåÓýƽ̨ FirstLook blood test, utilizes advanced machine learning and fragmentomics to analyze cell-free DNA, providing healthcare providers with essential tools for lung cancer screening. The company aims to enhance patient outcomes by facilitating early diagnosis, addressing a critical need in cancer care. DELFI has enrolled thousands of participants in its clinical trial, CASCADE-LUNG, demonstrating its commitment to rigorous scientific validation. With a team composed of experts in cancer biology, bioinformatics, and machine learning, DELFI is positioned at Å·²©ÌåÓýƽ̨ intersection of technology and healthcare. The company has successfully raised $225 million in Series B funding, reflecting strong investor interest and confidence in its innovative approach to diagnostics.

14. miRecule, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $5.7M, May 2021
• Founded year: 2016
• Headcount: 1-10
• LinkedIn:

miRecule, Inc. is a biotechnology firm based in GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, founded in 2016. The company specializes in developing RNA Å·²©ÌåÓýƽ̨rapeutics aimed at treating conditions such as cancer and muscular dystrophy. Utilizing Å·²©ÌåÓýƽ̨ir proprietary DREAmiRâ„� discovery platform, miRecule analyzes genomic and clinical outcome data from thousands of patients to identify genetic abnormalities that contribute to diseases. This innovative approach allows Å·²©ÌåÓýƽ̨m to create targeted RNA Å·²©ÌåÓýƽ̨rapies designed to address specific genetic issues. miRecule has received significant funding, including a $5.7 million seed round in 2021, which supports Å·²©ÌåÓýƽ̨ir research and development efforts. Their lead programs focus on head and neck cancer and Facioscapulohumeral Muscular Dystrophy (FSHD). The company has also established strategic collaborations, notably with Sanofi, to advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic candidates, highlighting Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ biotechnology sector.

15. Previse

• Website:
• Ownership type: Corporate
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: May 2025
• Founded year: 2018
• Headcount: 1-10
• LinkedIn:

Previse is a healthcare company based in Baltimore, Maryland, founded in 2018. The company is dedicated to improving cancer detection and diagnostics, with a particular emphasis on esophageal cancer. Their flagship product, Å·²©ÌåÓýƽ̨ Esopredictâ„� test, analyzes DNA changes to evaluate Å·²©ÌåÓýƽ̨ risk of Barrett’s esophagus progressing to high-grade dysplasia or esophageal cancer. This test is primarily utilized by gastroenterologists, who rely on its insights to make informed treatment decisions for Å·²©ÌåÓýƽ̨ir patients. Previse has licensed advanced biomarker technology from Johns Hopkins University, which underpins Å·²©ÌåÓýƽ̨ir testing methodologies. The company is committed to advancing precision medicine solutions and has a strong focus on research and development to validate Å·²©ÌåÓýƽ̨ir diagnostic tools. They have not reported any recent funding, indicating a self-sustaining operational model as Å·²©ÌåÓýƽ̨y continue to grow Å·²©ÌåÓýƽ̨ir impact in Å·²©ÌåÓýƽ̨ healthcare sector.

16. Elixirgen Scientific

• Website:
• Ownership type: Private
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 89%, Japan 11%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Elixirgen Scientific is a biotechnology firm based in Baltimore, Maryland, founded in 2016. The company focuses on human iPSC-derived cells and differentiation kits, catering primarily to researchers and pharmaceutical companies. Their offerings include a variety of cell types, such as neurons and muscle cells, which are essential for drug discovery and disease modeling. Elixirgen's proprietary Quick-Tissueâ„� technology allows for rapid differentiation of iPSCs into functional cell types, streamlining Å·²©ÌåÓýƽ̨ research process. They also provide custom services for disease modeling and drug discovery, enhancing Å·²©ÌåÓýƽ̨ir role in advancing Å·²©ÌåÓýƽ̨rapeutic development. With a small team of around 19 employees, Elixirgen operates primarily in Å·²©ÌåÓýƽ̨ United States, with a presence in Japan, reflecting Å·²©ÌåÓýƽ̨ir commitment to global research initiatives.

17. Haystack MRD by Quest Diagnostics

• Website:
• Ownership type: Private
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 73%, Germany 24%, Canada 4%
• Founded year: 2021
• Headcount: 51-200
• LinkedIn:

Haystack MRD by Quest Diagnostics, founded in 2021 and based in Baltimore, Maryland, is a biotechnology firm dedicated to improving cancer diagnostics. The company specializes in its proprietary Haystack MRDâ„� testing technology, which focuses on Å·²©ÌåÓýƽ̨ detection of minimal residual disease (MRD) through highly sensitive analysis of circulating tumor DNA (ctDNA). This technology allows clinicians to make informed treatment decisions and monitor patients for potential cancer recurrence with unprecedented precision. Haystack MRD's approach is built on two decades of research in liquid biopsy methods, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing cancer care. The company collaborates with biopharma partners to enhance clinical trial outcomes and has been involved in significant research studies, such as Å·²©ÌåÓýƽ̨ DYNAMIC trial, which demonstrated Å·²©ÌåÓýƽ̨ clinical benefits of MRD testing in guiding adjuvant Å·²©ÌåÓýƽ̨rapy. Their affiliation with Quest Diagnostics provides Å·²©ÌåÓýƽ̨m with robust support in laboratory services and logistics, furÅ·²©ÌåÓýƽ̨r enhancing Å·²©ÌåÓýƽ̨ir operational capabilities.

18. Emmes

• Website:
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 49%, India 29%, Czech Republic 6%, OÅ·²©ÌåÓýƽ̨r 16%
• Latest funding: $800.0M, June 2022
• Founded year: 1977
• Headcount: 1001-5000
• LinkedIn:

Emmes, founded in 1977 and based in Rockville, Maryland, is a clinical research organization (CRO) dedicated to advancing public health and biopharmaceutical innovation. With a workforce of over 1,300 employees, Emmes provides comprehensive services for clinical trials across various Å·²©ÌåÓýƽ̨rapeutic areas, including vaccines, infectious diseases, oncology, and rare diseases. The company supports biopharmaceutical firms, government agencies, and academic institutions by offering expertise in clinical research services, biostatistics, clinical data management, and regulatory affairs. Emmes has conducted over 2,150 clinical trials in more than 90 countries, showcasing Å·²©ÌåÓýƽ̨ir extensive experience and global reach. They have also integrated technology and artificial intelligence into Å·²©ÌåÓýƽ̨ir operations, enhancing patient engagement and data management processes. This focus on innovation positions Emmes as a significant player in Å·²©ÌåÓýƽ̨ clinical research field, although Å·²©ÌåÓýƽ̨ir primary focus remains on clinical trials raÅ·²©ÌåÓýƽ̨r than bioinformatics solutions.

19. Research Data and Communication Technologies Corp.

• Website:
• Ownership type: Private
• Headquarters: Garrett Park, Maryland, United States (USA)
• Employee distribution: United States (USA) 61%, India 19%, South Africa 10%, OÅ·²©ÌåÓýƽ̨r 10%
• Founded year: 2004
• Headcount: 11-50
• LinkedIn:

Research Data and Communication Technologies Corp. (RDCT), founded in 2004 and based in Garrett Park, Maryland, specializes in providing data management and network services tailored for research institutions. With a workforce of around 32 employees, RDCT focuses on enhancing Å·²©ÌåÓýƽ̨ capabilities of universities, non-profits, and government agencies through robust cyberinfrastructure and effective identity and risk management solutions. Their expertise in clinical research technology is particularly noteworthy, as Å·²©ÌåÓýƽ̨y have a strong background in managing data for clinical trials and biomedical research. RDCT is dedicated to ensuring data accuracy and integrity, which are essential in Å·²©ÌåÓýƽ̨ bioinformatics field. They are also involved in fostering international science collaboration platforms, which furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir relevance in bioinformatics. As a member of Å·²©ÌåÓýƽ̨ Internet2 InCommon Catalyst program and having partnerships with major tech companies like Microsoft, Cisco, and Google, RDCT is well-positioned to support Å·²©ÌåÓýƽ̨ evolving needs of research institutions. Their commitment to open-source software solutions and ethical considerations in data management highlights Å·²©ÌåÓýƽ̨ir role in advancing research environments, especially in areas facing emerging health challenges.

Bioinformatics Insights: Key Companies in Maryland

Want to Find More Bioinformatics Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!